ketanserin has been researched along with Allergic Contact Dermatitis in 2 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effect of vasoactive intestinal peptide (VIP) and of serotonin and its antagonists on the challenge phase of allergic contact dermatitis in humans were tested." | 7.70 | Inhibitory effect of vasoactive intestinal peptide on the challenge phase of allergic contact dermatitis in humans. ( Lundeberg, L; Mutt, V; Nordlind, K, 1999) |
| " To investigate their potential immunomodulating role in established allergic contact dermatitis in man, the following neuromediators were tested: vasoactive intestinal polypeptide (VIP), serotonin, and the serotonin antagonists ketanserin, methiotepine and ICS-205-930." | 7.69 | Inhibitory effect of vasoactive intestinal polypeptide and ketanserin on established allergic contact dermatitis in man. ( Bondesson, L; Lidén, S; Mutt, V; Nordlind, K, 1996) |
| " The effect of vasoactive intestinal peptide (VIP) and of serotonin and its antagonists on the challenge phase of allergic contact dermatitis in humans were tested." | 3.70 | Inhibitory effect of vasoactive intestinal peptide on the challenge phase of allergic contact dermatitis in humans. ( Lundeberg, L; Mutt, V; Nordlind, K, 1999) |
| " To investigate their potential immunomodulating role in established allergic contact dermatitis in man, the following neuromediators were tested: vasoactive intestinal polypeptide (VIP), serotonin, and the serotonin antagonists ketanserin, methiotepine and ICS-205-930." | 3.69 | Inhibitory effect of vasoactive intestinal polypeptide and ketanserin on established allergic contact dermatitis in man. ( Bondesson, L; Lidén, S; Mutt, V; Nordlind, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bondesson, L | 1 |
| Nordlind, K | 2 |
| Mutt, V | 2 |
| Lidén, S | 1 |
| Lundeberg, L | 1 |
2 other studies available for ketanserin and Allergic Contact Dermatitis
| Article | Year |
|---|---|
Inhibitory effect of vasoactive intestinal polypeptide and ketanserin on established allergic contact dermatitis in man.
Topics: Adjuvants, Immunologic; Cells, Cultured; Dermatitis, Allergic Contact; DNA; Enzyme-Linked Immunosorb | 1996 |
Inhibitory effect of vasoactive intestinal peptide on the challenge phase of allergic contact dermatitis in humans.
Topics: Adult; CD4 Antigens; Cell Division; Dermatitis, Allergic Contact; DNA; Female; HLA-DR Antigens; Huma | 1999 |